{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:08:39Z","timestamp":1778749719166,"version":"3.51.4"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02096-1","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:01:07Z","timestamp":1771934467000},"page":"693-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scoping review of apixaban and rivaroxaban dosing for atrial fibrillation and venous thromboembolism in advanced chronic kidney disease"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7027-8872","authenticated-orcid":false,"given":"Sophie","family":"Gillis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5285-753X","authenticated-orcid":false,"given":"Emma","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-1600","authenticated-orcid":false,"given":"Jennifer","family":"Pitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-4437","authenticated-orcid":false,"given":"Shanna","family":"Trenaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-4365","authenticated-orcid":false,"given":"Marisa","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-8036","authenticated-orcid":false,"given":"Chiranjeev","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9002-5011","authenticated-orcid":false,"given":"Christopher","family":"Daley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-6709","authenticated-orcid":false,"given":"Karthik","family":"Tennankore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-5886","authenticated-orcid":false,"given":"Louise","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-5740","authenticated-orcid":false,"given":"Jo-Anne","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"3","key":"2096_CR1","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395. https:\/\/doi.org\/10.1016\/S2214-109X(23)00570-3.","journal-title":"Lancet Glob Health"},{"key":"2096_CR2","unstructured":"Kidney Foundation. Facing the facts: includes highlights from the organ replacement in canada: CORR annual statistics, (2021). Kidney Foundation; 2023. https:\/\/kidney.ca\/KFOC\/media\/images\/PDFs\/Facing-the-Facts-2023-HIghlights-from-the-Annual-Statistics-on-Organ-Donation-June-2023.pdf. Updated 28.06.2023. Accessed 13 Jun 2025"},{"issue":"25","key":"2096_CR3","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","volume":"123","author":"A Alonso","year":"2011","unstructured":"Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.020982.","journal-title":"Circulation"},{"issue":"8","key":"2096_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/nep.12727","volume":"21","author":"JA Laukkanen","year":"2016","unstructured":"Laukkanen JA, Zaccardi F, Karppi J, et al. Reduced kidney function is a risk factor for atrial fibrillation. Nephrology. 2016;21(8):717\u201320. https:\/\/doi.org\/10.1111\/nep.12727.","journal-title":"Nephrology"},{"issue":"8","key":"2096_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27753","volume":"14","author":"S Gadde","year":"2022","unstructured":"Gadde S, Kalluru R, Cherukuri SP, et al. Atrial fibrillation in chronic kidney disease: an overview. Cureus. 2022;14(8):e27753. https:\/\/doi.org\/10.7759\/cureus.27753.","journal-title":"Cureus"},{"issue":"4","key":"2096_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.002097","volume":"1","author":"SE Nelson","year":"2012","unstructured":"Nelson SE, Shroff GR, Li S, et al. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc. 2012;1(4):e002097. https:\/\/doi.org\/10.1161\/JAHA.112.002097.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2096_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ccep.2020.11.001","volume":"13","author":"M Stefil","year":"2021","unstructured":"Stefil M, Nabrdalik K, Lip GYH. Renal disease and atrial fibrillation. Card Electrophysiol Clin. 2021;13(1):95\u2013112. https:\/\/doi.org\/10.1016\/j.ccep.2020.11.001.","journal-title":"Card Electrophysiol Clin"},{"issue":"7","key":"2096_CR8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","volume":"30","author":"P Masson","year":"2015","unstructured":"Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30(7):1162\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfv009.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2096_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","volume":"171","author":"JT Ha","year":"2019","unstructured":"Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2019;171(3):181\u20139. https:\/\/doi.org\/10.7326\/M19-0087.","journal-title":"Ann Intern Med"},{"issue":"11","key":"2096_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"10","key":"2096_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"12","key":"2096_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"5","key":"2096_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/MCP.0b013e32832ee371","volume":"15","author":"K Wattanakit","year":"2009","unstructured":"Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med. 2009;15(5):408\u201312. https:\/\/doi.org\/10.1097\/MCP.0b013e32832ee371.","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"2096_CR14","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/jth.14235","volume":"16","author":"KL Cheung","year":"2018","unstructured":"Cheung KL, Zakai NA, Callas PW, et al. Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study. J Thromb Haemost. 2018;16(9):1743\u201352. https:\/\/doi.org\/10.1111\/jth.14235.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2096_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, AMPLIFY-EXT Investigators, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1207541.","journal-title":"N Engl J Med"},{"issue":"9","key":"2096_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, AMPLIFY Investigators, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507.","journal-title":"N Engl J Med"},{"issue":"14","key":"2096_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR Buller","year":"2012","unstructured":"Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1113572.","journal-title":"N Engl J Med"},{"issue":"26","key":"2096_CR18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berlowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510. https:\/\/doi.org\/10.1056\/NEJMoa1007903.","journal-title":"N Engl J Med"},{"issue":"13","key":"2096_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1700518.","journal-title":"N Engl J Med"},{"issue":"5","key":"2096_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40256-024-00664-2","volume":"24","author":"SR Mandt","year":"2024","unstructured":"Mandt SR, Thadathil N, Klem C, et al. Apixaban use in patients with kidney impairment: a review of pharmacokinetic, interventional, and observational study data. Am J Cardiovasc Drugs. 2024;24(5):603\u201324. https:\/\/doi.org\/10.1007\/s40256-024-00664-2.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"2096_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000535546","volume":"55","author":"EJ Elenjickal","year":"2024","unstructured":"Elenjickal EJ, Travlos CK, Marques P, et al. Anticoagulation in patients with chronic kidney disease. Am J Nephrol. 2024;55(2):146\u201364. https:\/\/doi.org\/10.1159\/000535546.","journal-title":"Am J Nephrol"},{"issue":"1","key":"2096_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ekir.2024.10.016","volume":"10","author":"NW Lange","year":"2024","unstructured":"Lange NW, Muir J, Salerno DM. Direct oral anticoagulants in patients with ESRD and kidney transplantation. Kidney Int Rep. 2024;10(1):40\u201353. https:\/\/doi.org\/10.1016\/j.ekir.2024.10.016.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2096_CR23","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1055\/s-0038-1675578","volume":"2","author":"FECM Peeters","year":"2018","unstructured":"Peeters FECM, Dudink EAMP, Kimenai DM, et al. Vitamin K antagonists, non-vitamin K antagonist oral anticoagulants, and vascular calcification in patients with atrial fibrillation. TH Open. 2018;2(4):e391\u20138. https:\/\/doi.org\/10.1055\/s-0038-1675578.","journal-title":"TH Open"},{"issue":"23","key":"2096_CR24","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146(23):1735\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054990.","journal-title":"Circulation"},{"issue":"4","key":"2096_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","volume":"147","author":"H Reinecke","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023;147(4):296\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062779.","journal-title":"Circulation"},{"issue":"6","key":"2096_CR26","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","volume":"32","author":"AS De Vriese","year":"2021","unstructured":"De Vriese AS, Caluw\u00e9 R, Van Der Meersch H, et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. Clin J Am Soc Nephrol. 2021;32(6):1474\u201383. https:\/\/doi.org\/10.1681\/ASN.2020111566.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2096_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102584","volume":"8","author":"D Tham","year":"2024","unstructured":"Tham D, Zhao L, Yu W, et al. Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis. Res Pract Thromb Haemost. 2024;8(7):102584. https:\/\/doi.org\/10.1016\/j.rpth.2024.102584.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2096_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616.","journal-title":"Int J Soc Res Methodol"},{"key":"2096_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https:\/\/doi.org\/10.1186\/1748-5908-5-69.","journal-title":"Implement Sci"},{"issue":"7","key":"2096_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"10","key":"2096_CR31","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119\u201326. https:\/\/doi.org\/10.11124\/JBIES-20-00167.","journal-title":"JBI Evid Synth"},{"issue":"4","key":"2096_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.11124\/JBIES-21-00242","volume":"20","author":"MDJ Peters","year":"2022","unstructured":"Peters MDJ, Godfrey C, McInerney P, et al. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953\u201368. https:\/\/doi.org\/10.11124\/JBIES-21-00242.","journal-title":"JBI Evid Synth"},{"key":"2096_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel D, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021.","journal-title":"J Clin Epidemiol"},{"key":"2096_CR34","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia (2025) https:\/\/www.covidence.org\/. Accessed 05 May 2025"},{"key":"2096_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. Cochrane bias methods group; cochrane statistical methods group the cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"2096_CR36","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 11 Jun 2025"},{"key":"2096_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8870015","volume":"2021","author":"T Ahuja","year":"2021","unstructured":"Ahuja T, Sessa K, Merchan C, et al. Oral factor Xa inhibitors versus warfarin for the treatment of venous thromboembolism in advanced chronic kidney disease. Adv Hematol. 2021;2021:8870015. https:\/\/doi.org\/10.1155\/2021\/8870015.","journal-title":"Adv Hematol"},{"key":"2096_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-12-25","volume":"12","author":"RM Bauersachs","year":"2014","unstructured":"Bauersachs RM, Lensing AW, Prins MH, et al. Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12:25. https:\/\/doi.org\/10.1186\/1477-9560-12-25.","journal-title":"Thromb J"},{"issue":"2","key":"2096_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11239-022-02758-7","volume":"55","author":"L Cline","year":"2023","unstructured":"Cline L, Generoso EMG, D\u2019Apice N, et al. Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance <30 mL\/min. J Thromb Thrombolysis. 2023;55(2):355\u201364. https:\/\/doi.org\/10.1007\/s11239-022-02758-7.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2096_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1055\/s-0041-1740254","volume":"122","author":"AT Cohen","year":"2022","unstructured":"Cohen AT, Sah J, Dhamane AD, et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost. 2022;122(6):926\u201338. https:\/\/doi.org\/10.1055\/s-0041-1740254.","journal-title":"Thromb Haemost"},{"key":"2096_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijcard.2016.10.045","volume":"226","author":"S Gaertner","year":"2017","unstructured":"Gaertner S, Cordeanu EM, Nouri S, et al. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6-month outcomes. Int J Cardiol. 2017;226:103\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.045.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2096_CR42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11239-025-03075-5","volume":"58","author":"P Hanke","year":"2025","unstructured":"Hanke P, Domingo ME, Salanio G, et al. Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study. J Thromb Thrombolysis. 2025;58(3):380\u201390. https:\/\/doi.org\/10.1007\/s11239-025-03075-5.","journal-title":"J Thromb Thrombolysis"},{"key":"2096_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.thromres.2022.10.014","volume":"220","author":"P Knueppel","year":"2022","unstructured":"Knueppel P, Bang SH, Troyer C, et al. Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). Thromb Res. 2022;220:91\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2022.10.014.","journal-title":"Thromb Res"},{"issue":"11","key":"2096_CR44","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/bloodadvances.2019000972","volume":"4","author":"C Hanni","year":"2020","unstructured":"Hanni C, Petrovitch E, Ali M, et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv. 2020;4(11):2366\u201371. https:\/\/doi.org\/10.1182\/bloodadvances.2019000972.","journal-title":"Blood Adv"},{"issue":"6","key":"2096_CR45","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1060028019897053","volume":"54","author":"K Herndon","year":"2020","unstructured":"Herndon K, Guidry TJ, Wassell K, et al. Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veteran\u2019s affairs hospital. Ann Pharmacother. 2020;54(6):554\u201360. https:\/\/doi.org\/10.1177\/1060028019897053.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2096_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/87551225241247691","volume":"40","author":"C McClain","year":"2024","unstructured":"McClain C, Buckallew AR, Armbruster AL. Evaluation of apixaban use in patients with advanced kidney disease. J Pharm Technol. 2024;40(4):171\u20137. https:\/\/doi.org\/10.1177\/87551225241247691.","journal-title":"J Pharm Technol"},{"issue":"11","key":"2096_CR47","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1177\/1060028018781853","volume":"52","author":"JH Schafer","year":"2018","unstructured":"Schafer JH, Casey AL, Dupre KA, et al. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2018;52(11):1078\u201384. https:\/\/doi.org\/10.1177\/1060028018781853.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2096_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/phar.1905","volume":"37","author":"BE Stanton","year":"2017","unstructured":"Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37(4):412\u20139. https:\/\/doi.org\/10.1002\/phar.1905.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2096_CR49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/08998280.2021.1930967","volume":"34","author":"S Yun","year":"2021","unstructured":"Yun S, Sevinsky R, Spracklin T, et al. Relation of apixaban bleeding rates to dose in patients with chronic kidney disease. Proc (Bayl Univ Med Cent). 2021;34(5):555\u20139. https:\/\/doi.org\/10.1080\/08998280.2021.1930967.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2096_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.47583\/ijpsrr.2023.v82i02.001","volume":"82","author":"GB Chandra","year":"2023","unstructured":"Chandra GB, Kumar B, Singh S. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and chronic kidney disease: a randomised controlled trial. Int J Pharm Sci Rev Res. 2023;82:139\u201345. https:\/\/doi.org\/10.47583\/ijpsrr.2023.v82i02.001.","journal-title":"Int J Pharm Sci Rev Res"},{"key":"2096_CR51","doi-asserted-by":"publisher","DOI":"10.18087\/cardio.2020.11.n1322","volume":"60","author":"MI Chashkina","year":"2020","unstructured":"Chashkina MI, Andreev DA, Kozlovskaya NL, et al. Safety performance of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Kardiologiia. 2020;60:1322. https:\/\/doi.org\/10.18087\/cardio.2020.11.n1322.","journal-title":"Kardiologiia"},{"issue":"9","key":"2096_CR52","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","volume":"132","author":"CI Coleman","year":"2019","unstructured":"Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. 2019;132(9):1078\u201383. https:\/\/doi.org\/10.1016\/j.amjmed.2019.04.013.","journal-title":"Am J Med"},{"issue":"6","key":"2096_CR53","first-page":"353","volume":"23","author":"A Elis","year":"2021","unstructured":"Elis A, Klempfner R, Gurevitz C, et al. Apixaban in patients with atrial fibrillation and severe renal dysfunction: findings from a national registry. Isr Med Assoc J. 2021;23(6):353\u20138.","journal-title":"Isr Med Assoc J"},{"key":"2096_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.752468","volume":"8","author":"CM Fu","year":"2021","unstructured":"Fu CM, Li LC, Lee YT, et al. Apixaban vs. warfarin in atrial fibrillation patients with chronic kidney disease. Front Cardiovasc Med. 2021;8:752468. https:\/\/doi.org\/10.3389\/fcvm.2021.752468.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"2096_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","volume":"83","author":"EL Fu","year":"2024","unstructured":"Fu EL, Desai RJ, Paik JM, et al. Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study. Am J Kidney Dis. 2024;83(3):293-305.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.017.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2096_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100675","volume":"5","author":"JT Ha","year":"2023","unstructured":"Ha JT, Scaria A, Andrade J, et al. Safety and effectiveness of rivaroxaban versus warfarin across GFR levels in atrial fibrillation: a population-based study in Australia and Canada. Kidney Med. 2023;5(7):100675. https:\/\/doi.org\/10.1016\/j.xkme.2023.100675.","journal-title":"Kidney Med"},{"issue":"6","key":"2096_CR57","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/FJC.0000000000000911","volume":"76","author":"Z Heleniak","year":"2020","unstructured":"Heleniak Z, Papuga-Szela E, Krzysztof P, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease stage G4: a single-center experience. J Cardiovasc Pharmacol. 2020;76(6):671\u20137. https:\/\/doi.org\/10.1097\/FJC.0000000000000911.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"22","key":"2096_CR58","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","volume":"33","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehs274.","journal-title":"Eur Heart J"},{"key":"2096_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.amjcard.2024.11.033","volume":"238","author":"X Huang","year":"2025","unstructured":"Huang X, Xie D, Huang J, et al. Risk of bleeding, thrombosis and death among atrial fibrillation patients treated with oral anticoagulants across estimated glomerular filtration rates. Am J Cardiol. 2025;238:55\u201364. https:\/\/doi.org\/10.1016\/j.amjcard.2024.11.033.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2096_CR60","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11239-019-02028-z","volume":"50","author":"MJ Jones","year":"2020","unstructured":"Jones MJ, Eudaley ST, Moye RA, et al. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment. J Thromb Thrombolysis. 2020;50(2):330\u20136. https:\/\/doi.org\/10.1007\/s11239-019-02028-z.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2096_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100813","volume":"3","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Deray G, Floege J, et al. Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease. JACC: Advances. 2024;3(2):100813. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100813.","journal-title":"JACC: Advances"},{"issue":"1","key":"2096_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11239-023-02885-9","volume":"57","author":"Y Lin","year":"2024","unstructured":"Lin Y, Chao TF, Tsai ML, et al. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. J Thromb Thrombolysis. 2024;57(1):89\u2013100. https:\/\/doi.org\/10.1007\/s11239-023-02885-9.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2096_CR63","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40256-023-00611-7","volume":"23","author":"T Morimoto","year":"2023","unstructured":"Morimoto T, Hoshino H, Matsuo Y, et al. Safety and effectiveness of apixaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation stratified by renal function: a retrospective cohort study. Am J Cardiovasc Drugs. 2023;23(6):721\u201333. https:\/\/doi.org\/10.1007\/s40256-023-00611-7.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"2096_CR64","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3349\/ymj.2022.0455","volume":"64","author":"H Park","year":"2023","unstructured":"Park H, Yu HT, Kim TH, et al. Oral anticoagulation therapy in atrial fibrillation patients with advanced chronic kidney disease: CODE-AF registry. Yonsei Med J. 2023;64(1):18\u201324. https:\/\/doi.org\/10.3349\/ymj.2022.0455.","journal-title":"Yonsei Med J"},{"issue":"17","key":"2096_CR65","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","volume":"141","author":"JW Stanifer","year":"2020","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044059.","journal-title":"Circulation"},{"issue":"6","key":"2096_CR66","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s11739-024-03658-9","volume":"19","author":"R Talerico","year":"2024","unstructured":"Talerico R, Brando E, Luzi L, et al. Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience. Intern Emerg Med. 2024;19(6):1645\u201352. https:\/\/doi.org\/10.1007\/s11739-024-03658-9.","journal-title":"Intern Emerg Med"},{"key":"2096_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","volume":"223","author":"MR Weir","year":"2020","unstructured":"Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J. 2020;223:3\u201311. https:\/\/doi.org\/10.1016\/j.ahj.2020.01.010.","journal-title":"Am Heart J"},{"key":"2096_CR68","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.hrthm.2025.01.045","volume":"22","author":"MJ Wu","year":"2025","unstructured":"Wu MJ, Chen HH, Chen CH, et al. Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease. Heart Rhythm. 2025;22:1197\u2013209. https:\/\/doi.org\/10.1016\/j.hrthm.2025.01.045.","journal-title":"Heart Rhythm"},{"issue":"19","key":"2096_CR69","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","volume":"148","author":"Y Xu","year":"2023","unstructured":"Xu Y, Chang AR, Inker LA, et al. Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation. 2023;148(19):1445\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065614.","journal-title":"Circulation"},{"key":"2096_CR70","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034641","volume":"13","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ballew SH, Chang AR, et al. Risk of major bleeding, stroke\/systemic embolism, and death associated with different oral anticoagulants in patients with atrial fibrillation and severe chronic kidney disease. J Am Heart Assoc. 2024;13:e034641. https:\/\/doi.org\/10.1161\/JAHA.123.034641.","journal-title":"J Am Heart Assoc"},{"key":"2096_CR71","unstructured":"Bristol-Myers Squibb Canada and Pfizer Canada ULC (2025) Eliquis product monograph. Health Canada Drug Product Database. https:\/\/pdf.hres.ca\/dpd_pm\/00078262.PDF. Updated 10.01.2025. Accessed 19 Jun 2025"},{"key":"2096_CR72","unstructured":"Bayer Inc (2024) Xarelto product monograph. Health Canada Drug product Database.https:\/\/pdf.hres.ca\/dpd_pm\/00075106.PDF. Updated 27.03.2024. Accessed 19 Jun 2025"},{"key":"2096_CR73","unstructured":"Bristol-Myers Squibb Company and Pfizer Inc (2025) Eliquis Package Insert. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/202155s039s040lbl.pdf. Updated 04.2025. Accessed 19 Jun 2025"},{"key":"2096_CR74","unstructured":"Janssen Pharmaceuticals Inc., licensed from Bayer HealthCare AG (2023) Xarelto package insert. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022406s041lbl.pdf. Updated 02.2023. Accessed 19 Jun 2025."},{"key":"2096_CR75","unstructured":"Bristol-Myers Squibb\/Pfizer EEIG (2025) Eliquis summary of product characteristics. Eur Med Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf. Updated 28.04.2025. Accessed 19 Jun 2025"},{"key":"2096_CR76","unstructured":"Bayer AG (2024) Xarelto summary of product characteristics. Eur Med Agency.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf. Updated 12.09.2024. Accessed 19 Jun 2025"},{"issue":"6","key":"2096_CR77","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1060028020967635","volume":"55","author":"CYS Cheung","year":"2021","unstructured":"Cheung CYS, Parikh J, Farrell A, et al. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother. 2021;55(6):711\u201322. https:\/\/doi.org\/10.1177\/1060028020967635.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2096_CR78","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","volume":"41","author":"HY Chen","year":"2021","unstructured":"Chen HY, Ou SH, Huang CW, et al. Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: A systematic review and meta-analysis. Clin Drug Investig. 2021;41(4):341\u201351. https:\/\/doi.org\/10.1007\/s40261-021-01016-7.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2096_CR79","doi-asserted-by":"publisher","DOI":"10.31083\/RCM26736","volume":"26","author":"HM de Oliveira","year":"2025","unstructured":"de Oliveira HM, Barros LP, de Campos MCAV, et al. Anticoagulation strategies for atrial fibrillation in CKD stage G5 and dialysis patients: an updated scoping review. Rev Cardiovasc Med. 2025;26(3):26736. https:\/\/doi.org\/10.31083\/RCM26736.","journal-title":"Rev Cardiovasc Med"},{"key":"2096_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.885548","volume":"9","author":"TM Rhee","year":"2022","unstructured":"Rhee TM, Lee SR, Choi EK, et al. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:885548. https:\/\/doi.org\/10.3389\/fcvm.2022.885548.","journal-title":"Front Cardiovasc Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02096-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:15:58Z","timestamp":1778746558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02096-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02096-1","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors S.G, E.P, J.P, S.T, C.S, C.D, L.G have no financial interests. Author J.W. has received moderator honorarium from Otsuka and has received unrestricted investigator-initiated grant funding from Bayer Canada. Author K.T. has received honorarium for advisory board with Otsuka, Bayer, and Vifor Pharmaceuticals; has received unrestricted investigator-initiated grant funding from Otsuka. Autor M.B has received honorarium from Otsuka, and Bayer Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional ethics approval was not required for this scoping review. The study was registered with Open Science Framework.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to publish.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}